Interpreting Lambda Kappa Ratio in Plasma Cell Disorders

Diagnostic Significance

The National Comprehensive Cancer Network recommends that an abnormal lambda kappa ratio is defined as >4:1 or <1:2, indicating the presence of a clonal plasma cell population, which is essential for diagnosing multiple myeloma and related disorders 1
The kappa/lambda ratio helps establish clonality of plasma cells, which is essential for diagnosing multiple myeloma and related disorders, with a normal ratio range not explicitly defined in this context but implied to be between 1:2 and 4:1 2
In bone marrow assessment, an abnormal ratio reflecting the presence of an abnormal clone is defined as >4:1 (kappa predominant) or <1:2 (lambda predominant), and is used to confirm clonality in bone marrow plasma cells when at least 100 plasma cells are available for analysis 1

The National Comprehensive Cancer Network suggests that the lambda kappa ratio is used to confirm clonality in bone marrow plasma cells when at least 100 plasma cells are available for analysis, and is essential for diagnosing and monitoring light chain-only myeloma and nonsecretory myeloma 1, 4
The lambda kappa ratio is essential for diagnosing and monitoring light chain-only myeloma and nonsecretory myeloma, with the International Myeloma Society implying its importance in these contexts 2

The International Myeloma Society considers an abnormal free light chain ratio (≥100 for involved kappa or ≤0.01 for involved lambda) as a myeloma-defining event, indicating a higher risk of disease progression 3, 5

In bone marrow assessment, the lambda kappa ratio requires a minimum of 100 plasma cells for analysis, and is used to confirm stringent complete response (sCR) when combined with negative immunofixation and <5% plasma cells in bone marrow 1, 4
The serum free light chain assay has a normal ratio range of 0.26-1.65, and a highly abnormal ratio (≥100 for kappa or ≤0.01 for lambda) is considered a myeloma-defining event, according to the National Comprehensive Cancer Network 2, 3, 5

Renal impairment can cause elevated levels of both kappa and lambda chains, potentially masking an abnormal ratio, and serial measurements should use the same assay to ensure accurate relative quantification, as noted by the National Comprehensive Cancer Network and the International Myeloma Society 1, 2, 4
At least 100 plasma cells must be analyzed for accurate kappa/lambda ratio determination by immunohistochemistry or immunofluorescence, and the ratio should not be interpreted in isolation but in conjunction with other clinical and laboratory parameters, according to the National Comprehensive Cancer Network 1, 3, 4

A normal FLC ratio is required for stringent complete response (sCR) classification, and in patients without measurable serum and urine M-protein, disease progression is defined by an absolute increase >10 mg/dL in the difference between involved and uninvolved FLC levels, as defined by the National Comprehensive Cancer Network 1, 3